DARZALEX® + Velcade® (bortezomib) + dexamethasone
Significant improvement in PFS using DARZALEX®-based triplet therapy1
Median PFS had not yet been reached with DARZALEX® + Vd triplet therapy vs 7.2 months with Vd1
Complete response rate more than doubled with DARZALEX® + Vd
The majority (79%) of patients responded to DARZALEX® + Vd1
Deeper and sustained responses were demonstrated with DARZALEX® + Vd vs Vd1
- With DARZALEX® + Vd, median time to first response was 0.8 months (range: 0.7 to 4 months), median time to VGPR or better was 3.5 months (95% CI: 2.8, 4.2), and median time to CR or better was not yet reached (95% CI: 12.0, not estimable [NE])1,2
Median duration of response was not yet reached with DARZALEX® + Vd (range: 1.4+ to 14.1+ months) vs 7.9 months with Vd (range: 1.4+ to 12+ months), at a median follow-up of 7.4 months1
Daratumumab (DARZALEX®) in combination with lenalidomide and dexamethasone, or bortezomib and dexamethasone, is recommended by the NCCN Clinical Practice Guidelines in Oncology (NCCN Guidelines®) as a preferred Category 1* therapeutic option for previously treated multiple myeloma†
*Category 1=based upon high-level evidence, there is uniform National Comprehensive Cancer Network® (NCCN®) consensus that the intervention is appropriate.
†Referenced with permission from the NCCN Clinical Practice Guidelines in Oncology (NCCN Guidelines®): Multiple Myeloma V.2.2020. © National Comprehensive Cancer Network, Inc. 2020. All rights reserved. To view the most recent and complete version of the guideline, go online to www.nccn.org. NCCN makes no warranties of any kind whatsoever regarding their content, use or application and disclaims any responsibility for their application or use in any way.